StockData
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT) stock

BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/305% below fair value
$5.06−0.04 (-0.78%)

Close on Nov 19, 2026Market cap $9.75MP/E –Yield –

Bolt Biotherapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Bolt Biotherapeutics

Bolt Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Bolt Biotherapeutics figures

See a number that looks wrong?